How Do Oxygen, Hydrogen and Pollutants Influence the Regulation of our Glands and Cellular Power Plants?
How Do Oxygen, Hydrogen and Pollutants Influence the Regulation of our Glands and Cellular Power Plants?
Sybille Arnold, naturopath, Germany
An understanding of the biochemical role of oxygen and hydrogen in the regulation of the glands and the function of the mitochondria is very important today, as regulation is increasingly restricted by pollutants and various external stresses.
The importance of the topic of energy production and hormonal regulation is essential for health, vitality and well-being.
How can we use oxygen and hydrogen to support bioresonance therapy? And what information can help us as therapists to recognize the appropriate use for our patients?
Oxygen
Oxygen in cell function
The role of oxygen as the main player in cellular respiration supports ATP production in the mitochondria through phosphorylation. A high oxygen supply increases the efficiency of energy production.
The influence of oxygen on glands
Oxygen improves blood circulation and the metabolism of the endocrine glands (e.g. adrenal gland and thyroid gland), promotes hormone synthesis and hormone secretion.
Oxygen improves mental clarity, immune function and cellular recovery/regulation.
Hydrogen
Hydrogen in cell function
The role of hydrogen is the antioxidant effect of molecular hydrogen H2.
It reduces reactive oxygen species (ROS cause cell damage) through neutralization. Hydrogen protects mitochondria from oxidative stress.
The influence of hydrogen on glands
Hydrogen improves the function of the pituitary gland and regulates hormone systems. It promotes insulin sensitivity and supports hormonal balance and cell regeneration.
Hydrogen has an anti-inflammatory effect and promotes regeneration and stress management.
Place these ampoules in the input cup and test/treat with program 192. Although these ampoules are prioritized, the entire set can be tested and applied for optimal results.
Conclusion:
By applying these protocols using BICOM bioresonance, you can provide a highly effective treatment for chronic stress. This approach may prevent the onset of autoimmune conditions and other chronic illnesses. For patients with existing health issues, addressing chronic stress as an underlying cause will contribute to long-term treatment success.
Pollutants
Heavy metals (e.g. lead, mercury), environmental toxins (e.g. pesticides, plasticizers), air pollutants (e.g. nitrogen oxides, particulate matter) impair the mitochondria by inhibiting ATP production and blocking the respiratory chain.
Effect on the glands
Disruption of thyroid function due to heavy metals and inhibition of hormonal signaling pathways, e.g. in the adrenal gland.
The combined effects of chronic exposure to pollutants lead to exhaustion and hormonal imbalance.
The holistic approach of hydrogen
The element H is the first in the periodic table and also the most abundant element in the universe. The Big Bang theory states that hydrogen was the first element from which increasingly complex structures developed.
The biological hydrogen NADH
In our body, hydrogen H is bound to NAD (nicotinamide adenine dinucleotide hybrid), also known as nicotinamide vitamin B3, which our body produces itself.
This NADH is involved in more than a thousand metabolic reactions and is the most important of all coenzymes found in the organism. This is why NAD is also called coenzyme-1.
The heart and brain require the most energy, which is why they have the highest NADH content of all organs. Also liver, kidneys and lungs receive more energy from NADH.
Effect of NADH in the body
In addition to those already mentioned above:
Regeneration of DNA, regulation of blood pressure and cholesterol levels, increases interleukin-6 leukocytes, increases the production of the neurotransmitters adrenaline and dopamine, protects one of the most important enzymes in the brain, tyrosine hydroxylase, and thus has a preventive effect on neurodegenerative diseases such as Alzheimer's or Parkinson's.
In homeopathy, the 7 series are regarded as phases of human development from birth to death.
Hydrogen can be found in row 1 and column 1.
Hydrogenium is about the beginning, the beginning of existence itself. "I find it hard to find a beginning!"
It is the first manifestation of a structural problem. Dr. Jayesh Shah writes:
"They have no self-worth. They have nothing. They are afraid of not being noticed."
This is one of the most primal basic fears that we often see in our patients. The whole life and world situation has also shaken many people.
We often find that our patients have little clarity about who they really are. They often live their lives unconsciously with the fear of going completely unnoticed. They identify with the you, the outside, and their actual inner energy and strength continue to diminish.
Hydrogen can provide helpful energy here.
The holistic approach of oxygen
The element 0 is in the second row of the periodic table.
Oxygen is produced in relatively large quantities in giant stars by helium burning. There is 21% oxygen on earth.
In combination with hydrogen, it becomes highly explosive, so that it can even be used to fire rockets.
Proportion of chemical elements in the human body by weight: Oxygen 56.1 % Hydrogen 9.3 %
Oxygen 0 can be found in row 2 and column 16.
Oxygenium in homeopathy
The second series is basically about the question: "Can I do it on my own?"
This is the relationship with the parents, this help line — this support that is also perceived as suffocating and destructive at the same time. It's about a lack of oxygen/air and that is detrimental to my survival. However, at the same time, even though I'm almost there, I lack
the confidence to keep the goal in front of me and find the energy to get there. Instead, I give up! (Column 16)
It's also about the issue of values that you've been taught and that give you security and at the same time the feeling of being suffocated by them.
It deals with topics that have to do with separation and being on your own. The ego is barely developed and so self-care is difficult.
Oxygen can help us to breathe a sigh of relief and take space for ourselves again.
Practical solutions for our patients
Oxygen and hydrogen supply through targeted measures as walks in the forest, outdoor sports, drinking ionized water enriched with hydrogen.
Avoid harmful substances and establish healthy lifestyle habits.
The balance of oxygen and hydrogen is crucial for energy production and regeneration. Reducing pollutants is essential for long-term health.
Bioresonance therapy: new programs Therapy concept Sibylle Arnold
Basic regulation: 1st session
Release blockages
Ai Normal range, BP2, 963 Hz, wobbling yes Amplification variant constant 4
Amplification 9.0, interval yes, time: 30 min
I: Belly rectangular applicator
O: Back modulation mat + hands ball applicators
Triggering
A Normal range, BP2, 1111 Hz, wobbling yes Amplification variant constant 4
Amplification 3.0, interval yes, time: 21 min
I: Hands ball applicators
O: Back modulation mat
Filling
H Normal range, BP2, 1111 Hz, wobbling yes Amplification variant constant 4
Amplification 3.0, interval yes, time: 21 min
I: Hands ball applicators
O: Back modulation mat
Cell regulation rd session
1. Release mitochondrial blockage
Ai Normal range, BP2, 2680 Hz, wobbling yes Amplification variant constant 4
Amplification 34, interval yes, time: 9 min
I: Solar plexus square applicator
O: Back modulation mat + hands ball applicators Ch2 oxygen and/or hydrogen
2. Mitochondria regulation/filling
H Normal range, BP2, 2680 Hz, wobbling yes
Amplification variant constant 4
Amplification 12, interval yes, time: 12 min
I: Solar plexus square applicator
O: Back modulation mat + hands ball applicators
Ch2 oxygen and/or hydrogen
Metabolic programs to regulate oxygen/hydrogen uptake
Test which program is right for you to start with. Programs 1-3 have an increasing effect.
Cellular respiration regeneration 3rd session
Activate cellular respiration light
H+Di Normal range, BP2, 3690 Hz, wobbling yes
Amplification variant SW falling 5, Di 3.0, Di speed 3 sec
Interval yes, time: 27 min
I: Lung front square applicator, lung rear rectangular applicator
O: Narrow, long applicator around the head/forehead, modulation mat on the back, pulled up Oxygen and/or hydrogen input ampoule, Herkimer diamond
Ch2 oxygen and/or hydrogen, if not tested in the input!
Activate cell respiration medium
H+Di Normal range, BP2, 7960 Hz, wobbling yes
Amplification variant SW symmetrical 6, Di 9.0, Di speed 12 sec
Interval yes, time: 30 min
I: Lung front square applicator, lung rear rectangular applicator
O: Narrow, long applicator around the head/forehead, modulation mat on the back, pulled up Oxygen and/or hydrogen input ampoule, Herkimer diamond
Ch2 oxygen and/or hydrogen, if not tested in the input!
Activate cellular respiration deep
H+Di Normal range, BP2, 8930 Hz, wobbling yes
Amplification variant SW symmetrical 6, Di 8.0, Di speed 9.9 sec Interval yes, time: 30 min
I: Lung front square applicator, lung rear rectangular applicator
O: Narrow, long applicator around the head/forehead, modulation mat on the back, pulled up Oxygen and/or hydrogen input ampoule, Herkimer diamond
Ch2 oxygen and/or hydrogen, if not tested in the input!
Ch2: Ampoules and Herkimer Diamond
I prepared the ampoules as follows:
- Oxygen ampoule was filled from oxygen device.
- Ampoule of hydrogen was filled with hydrogen-enriched water.
Herkimer diamond
The Herkimer "diamond" comes mainly from the USA and was already known there to the Mohawk and Iroquois Indians. It is a quartz crystal and is characterized by its striking purity and diamond-like appearance and usually occurs as a double-ender (with two points).
These two peaks also symbolize the connection between heaven and earth.
Herkimer diamonds are nicknamed "diamonds" because of their remarkable clarity and brilliance. In the world of crystal meanings, they symbolize clarity, purity and spiritual attunement. They are believed to enhance inner vision and help people see their true selves and recognize the purity within.
Physical effect
The Herkimer diamond can provide more vitality, relieve tension and have a positive effect on the brain, nerves and senses. It is also said to support healing processes, strengthen the immune system, prevent inflammation and infections and detoxify the entire body.
Herkimer diamond as a healing stone: It promotes clarity of mind and supports meditation by facilitating access to higher states of consciousness. It also helps to release emotional blockages and increase general well-being.
The Herkimer diamond is said to have metaphysical properties, including healing, increasing spiritual energy and opening the crown and third eye chakras. The Herkimer diamond, also known as the 'stone of attunement', can supposedly be used to help people have clearer perceptions.
I wish you much joy with these new programs and may they be helpful for you, the people and everywhere in the world. Thank you.
References:
Scholary article on molecular hydrogen and cell health
WHO reports on air pollutants
Textbooks on biochemistry and endocrinology
Homeopathy and the structure of the periodic table, Bhavisha Joshi Insights into the periodic table, Dr. Jayesh Shah
NADH The biological hydrogen, Prof. Dr. Dr. George D. Birkmayer
Case study: No more Detectable Brain Metastases
Antonina Rome, MD, Slovenia
INTRODUCTION
Oncology has made a remarkable progress in the last decade, especially at the molecular level, where tumor research has enabled the development of new targeted therapies. Understanding the specific genetic mutations and signaling pathways associated with cancer initiation and progression has enabled the development of personalized approaches that target the specific characteristics of individual tumors. Among the most important advances in this field is the development of targeted drugs, such as Brigatinib, which target specific oncogenic mutations associated with tumor metastasis, allowing for a more effective treatment in patients with advanced cancers.
Recent years have also seen breakthroughs in immunotherapy. Immune checkpoint inhibitors have been developed that allow the body to recognize and attack cancer cells. These drugs allow long periods of remission, which in a certain proportion of patients also lead to a cure of the disseminated cancer. The only problem is the frequent development of autoimmune diseases with the use of such drugs.
Despite all the advances, only a certain proportion of patients respond to the new advanced oncological therapies. Combinations of immunotherapy with conventional chemotherapy, radiotherapy and targeted drugs are being emphasized and explored to achieve better therapeutic outcomes.
BICOM bioresonance as important contribution to a holistic treatment approach, is gaining ground in the modern treatment of cancer patients. Despite the promising results reported by many therapists in their daily practice, one of the key problems remains the lack of concrete statistical studies that would allow a broader and more systematic treatment of bioresonance in the context of oncological therapy. The lack of standardized therapeutic protocols complicates our work in integrative practice.
The case presented in this article is part of a broader concept that goes beyond this single case. Cancers have become very specific, individually targeted to specific mutations, which means that a systematic approach to the management of these patients is also a necessity in BICOM bioresonance. As both in-vivo and in-vitro bioresonance research is often expensive and difficult to access, we need to look for alternative solutions for systematic data collection that will support our therapies without large financial resources. Thus, in addition to presenting a case and a bioresonance treatment approach, I also present possible solutions through retrospective analysis, identification of errors in practice, establishment of performance criteria, comparison tables, traceability and optimization of protocols to increase the efficacy of treatment and the visibility of BICOM bioresonance in oncology.
CASE STUDY AND THEORY BACKGROUNDS ANAMNESIS
A 52-year-old man, a known allergy sufferer, had been relieving his hay fever symptoms for years with informed bioresonance drops. He did not want to attend bioresonance. He has had 2 vaccinations against COVID-19 with Vaxzevria AZ (June 2021). In January 2022, he noticed a deterioration in physical performance while skiing. This was followed by bloody sputum on several occasions while out for a walk in the mornings. X-ray confirmed a 33mm tumor lesion in the left upper lung lobe with suspicious satellite tumors and carcinomatous lymphangitis in the same lobe, enlarged lymph nodes adjacent to the bronchus. He was immediately referred to the Pulmonary Department for tumor infiltrates of the Golnik Clinic, where further investigations ruled out metastases and histological confirmation of non-small cell carcinoma. He has pre-existing chronic bronchitis and is being treated with antibiotics prophylactically for invasive investigations.
Diagnosis: non-small cell adenocarcinoma of the left upper lobe (NSCLC), ALK positive*, PDL1** 20%, T3N1M0.
Treatment of choice: surgery, 4 cycles of chemotherapy with pemetrexed/cisplatin, radiotherapy
Follow-up examinations: PET-CT, MRI
In March 2022, a lobectomy of the left upper lobe of the lung is performed. As the conglomerate of carcinomatous lymph nodes is growing into the main trunk of the left pulmonary artery and fouling and tracting the N. phrenicus, complete resection of the lymph nodes is not feasible.
In April/May 2022 he receives 4 cycles of chemotherapy (pemetrexed/cisplatin) every
2 weeks, which he tolerates well, with no toxic comorbidities, blood counts are within normal limits. WHO Performance Status 0 to 1 (meaning he is fit for aggressive therapies). He also receives 30 fractions of radiotherapies. Support with folic acid and B12 i.m. Severe fatigue after radiotherapy.
Completion of treatment in July 2022. Control scan every 3 months shows stagnation at the primary site and regression of pathological lymph nodes in the left hilus, and exclusion of any new developed lesions and other pathologies. The stable condition persists until November 2023 (17 months).
* Approximately 2 to 7 out of 100 people with NDLP have an ALK gene alteration in their tumor DNA genetic blueprint. People with this gene change are said to have ALK-positive non-small cell lung cancer (ALK+ NDRP). In ALK+ NDRP, the biggest problem is the spread of the disease, especially to the central nervous system (brain and meninges).
** PDL1 refers to the programmed death ligand 1 (PD-L1) protein on the surface of tumor cells or
immune cells. This protein is involved in a mechanism of immune inhibition that allows tumors to evade destruction by the immune system. 20% reflects the percentage of PDL1 present on tumor or immune cells in a tissue sample and predicts the percentage of successful therapy. Immunotherapy blocks PDL1 and allows T cells to attack tumor cells again.
In August 2023, he survives a severe myocardial infarction, a stent is inserted in the LAD. He receives protective therapy (Aspirin, statin Sorvitimb, Bioprexanil).
MRI in November 2023 describes new lesions (2 lesions of 4mm and 1 lesion of 5mm right frontal), while the primary lesions in the chest remain in regression. The patient has no clinical signs or symptoms on the CNS. The consilient decides on systemic treatment with Brigatinib*** — an ALK inhibitor, which he starts on 4.12.2023.
A follow-up MRI after 3 months, i.e. in February 2024, shows regression of the brain tumors. CT of the thorax remains unchanged, with stagnation of lesions that were inoperable.
Head MRI June 2024 and January 2025 no longer describe intracranial pathological staining, i.e. no metastases are seen, only one small avital metastatic remnant remains. The disease is almost in complete remission. The patient remains on Brigatinib and BICOM bioresonance therapies as he carries a ticking time bomb that has yet to be resolved.
KEY THERAPY TIPS FOR TUMOR PATIENTS
1. Initial Discussion and Reducing Fear:
• It's vital to conduct a constructive, open, and encouraging discussion that helps relieve the patient's fear. Fear can be more detrimental than the disease itself. "The greatest and most important task as bioresonance therapists is a constructive, open, honest, and encouraging INITIAL DISCUSSION, which first and foremost frees the patient of their crippling fear."
[RTI Volume 37, May 2013, Marianne Thalmann]
*** WHAT IS BRIGATINIB?
Brigatinib is used to treat non-small cell lung cancer (NSCLC), which has a change in the ALK gene in its tumor genetic make-up. In ALK+ NSCLC, the biggest problem is the spread of the disease, especially to the central nervous system (brain and meninges). The aim of Brigatinib is to stop further spread of the disease and to reduce the cancer already present in an existing tumor and stop it spreading throughout the body.
How does brigatinib work? A change in the ALK gene causes cells to behave unusually. Healthy cells normally grow at a certain rate, then die and are replaced by new cells. When the ALK gene is altered, this process is not normal, and the cells continue to grow and multiply, spreading to other parts of the body through the blood and lymph through blood vessels and lymph ducts. The abnormal gene produces a protein called a kinase that promotes the growth of cancer cells. The drug brigatinib blocks the action of this protein, slowing the growth and spread of tumors.
However, brigatinib does not usually act directly on primary cancer cells in the lung, but mainly on those containing the ALK mutation that cause the disease to spread, including metastases. The drug is highly specific for ALK-mutated cancer cells, allowing targeted therapy with fewer side effects compared to some other cancer drugs.
The drug may affect liver enzyme surges, so regular monitoring is needed. Otherwise, the patient has no potential side-effects of the drug, such as nausea, fatigue, diarrhoea, cough, headache, as well as no neurological seizures.
Use an in-depth questionnaire with the patient and before the initial session to form a preliminary plan.
2. Pathophysiology Insight:
Make a thorough study of tumor characteristics, medical therapy plans and its side effects beforehand
prepare a criteria chart (attached) for your patient and his type of tumor
Bioresonance therapists can offer unique assistance to patients willing to embark on the road to self-healing. While its an arduous path, it can be significantly beneficial. AKI tumor seminar offers incredible level of knowledge.
Continuous Monitoring: Consistent observation of priority principles helps in identifying interim relapses, which are often emotional stresses needing immediate attention.
3. Treatment Strategy:
The therapy aims at elimination stimulation, detoxification, immune enhancement, healthy tissue support and direct action on cancerous tissues.
It addresses both physical and energetic imbalances in the patient's body.
Engage patients actively in their healing process, emphasizing the need for consistent self-help efforts.
Follow his reactions to BICOM therapy and especially to medical therapies and schedule your therapies accordingly
If the patient does not respond to its own frequencies, engage only CTT ampules, mainly DC 1 and DC 2 as these are CTT ampoules that are primarily used in cancer treatments to identify and neutralize specific energetic imbalances associated with the disease.
Alternate weekly tumor treatment with chemo detox. Depends on patient but not engage both at the same time, the body might not cope with too much frequency demands.
Take into consideration the phases of treatment the patient is in as follows:
1.INITIAL PHASE
MEDICINE: still investigating the tumor, scans, biopsies
BICOM: get patient ready — basic programs, blockages, elimination support
2.TREATMENT PHASE
MEDICINE: operation, chemotherapy, radiotherapy
BICOM: alternate weekly between tumor treatment with DC1, DC2 (1 week) and treatment support by chemo/radio elimination (2 week)
3.STABILIZING PHASE
MEDICINE: usually 3 monthly follow-ups if the tumor is in regression, without therapy
BICOM: 2 week treatments of root causes as well as DC sets, especially DC2 immunology and healthy tissue support
4. METASTATIC PHASE
MEDICINE: targeted therapies, immunotherapy, chemotherapy, or radiotherapy if applicable
BICOM: supportive treatments, medication boost treatments, boosting immune system, managing metastases, reducing side effects, treatment protocols tailored to individual needs
5. PALLIATIVE PHASE
MEDICINE: focus on symptom management, pain relief, and improving quality of life
BICOM: focus on pain management, energy support, emotional and mental wellbeing, quality of life optimization, gentle detoxification, and comfort care
INTERPRETATIONS OF BICOM CANCER TREATMENT WITH OUR PATIENT
In the medical history, we have already focused on the time course of the patient's illness. In the following, we will now evaluate BICOM therapy in our patient on the basis of the phases described above. At the same time, I have also introduced the errors in the work that we observed in the retrograde analysis of the performance of the work. Better solutions are also presented orally in the Congress lecture.
Table 1: Phases of treatment
STANDARDIZING EVALUATION OF BICOM TREATMENT
How to evaluate the success of bioresonance therapies without control groups, other references, etc. What is the survival of patients or the success rate of chemotherapy? For this purpose I have prepared a table of criteria and a descriptive explanation by which oncological medicine measures the success of treatments. We can join in with our own treatment, so that we always aim for our patients to reach the maximum level of the criterion. First, let's look at the general theory of criteria. Then I show the comparisons in a table. We can quickly see that our patient from this case reaches or even exceeds the upper limits of the expected statistics.
GENERAL INFORMATION ON THE CRITERIA
When reporting the success of therapies in treating tumors, it is crucial to use standardised criteria to objectively assess the tumor's response to treatment. This allows comparability between studies and improves the quality of clinical research.
Main criteria for assessing tumor response:
1. RECIST (Response Evaluation Criteria in Solid Tumors): standardised criteria for assessing changes in tumor size during treatment. Used mainly in clinical trials to evaluate the effectiveness of therapies.
Four response categories:
Complete response (CR): Disappearance of all target lesions.
Partial response (PR): At least 30% reduction in the sum of the diameters of the target lesions.
Stable disease (SD): Insufficient reduction for partial response or increase for progressive disease.
Progressive disease (PD): At least 20% increase in the sum of the diameters of the target lesions or the appearance of new lesions.
Toxicity assessment criteria (e.g. CTCAE — Common Terminology Criteria for Adverse Events): Standardized criteria for reporting adverse effects of treatment. They allow the safety of therapies to be assessed and compared between different studies.
Criteria for assessing survival:
Rate of response to treatment: Percentage of patients who achieve a complete or partial response.
Overall Survival (OS): Time from initiation of treatment to death from any cause.
Progression-Free Survival (PFS): Time from initiation of treatment until disease progression or death.
Time to Progression (TTP): Time from initiation of treatment to first documented disease progression.
We include such criteria to monitor the success of concomitant BICOM bioresonance treatment, which will contribute to improved data interpretation, therapeutic decision making and the development of new protocols and therapies, the optimization of existing treatments and, most importantly, to further improve the visibility of BICOM bioresonance in integrative oncology.
CONCLUSION
The treatment of lung adenocarcinoma with brain metastases has been very successful. The patient's prognosis is promising due to the favorable response to the overall therapeutic approach, but long-term cardiac health care is crucial to reduce the risk of recurrence or cardiovascular complications. As well as the continued treatment of the tumor lymph nodes in the chest, which still present the possibility of genetic mutation and a new lesion, is necessary. The patient remains under our care.
In this context, the creation of an AKI Task Force is crucial, as it would allow the development of a methodology for monitoring therapeutic procedures, tracking errors and setting clear benchmarks for success. This would allow objective assessment of effectiveness and comparability of results, which is essential for progress in this field. My contribution is not just a description of one patient, but a search for solutions for a broader framework to systematize patient management and monitor the success of bioresonance therapies in integrative oncology.
I invite all interested therapists to join the BICOM group of therapists for the development of bioresonance in oncology, abbreviated BIONCO.
LITERATURE
Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992 Nov;10(4):239-53. doi: 10.1007/BF00944177. PMID: 1487397.
Sause W, Kolesar P, Taylor IV IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Dar AR, Turrisi A. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000 Feb;117(2):358-64. doi: 10.1378/chest.117.2.358. PMID: 10669675.
Gebauer B, Bohnsack 0, Riess H. [Radiological evaluation of tumor response in oncological studies (tumor response evaluation)]. Rofo. 2011 Aug;183(8):695-703. doi: 10.1055/s-00291246074. PMID: 21391174. [Article in German]
Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced nonsmall-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78. doi: 10.1016/s0360-3016(98)00251-x. PMID: 9806503.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aidcncr2820470134>3.0.co;2-6. PMID: 7459811.
Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993 Apr;67(4):773-5. doi: 10.1038/bjc.1993.140. PMID: 8471434.
University Clinic Golnik. Informational publication for lung cancer patients. Golnik: University Clinic Golnik; 2021.
Institute of Oncology Ljubljana. Mojca Unk, MD. Discussion about Brigatinib, informational publication. Ljubljana: Institute of Oncology Ljubljana; 2020.